Crinetics Pharmaceuticals (CRNX) Gross Margin (2025 - 2026)

Crinetics Pharmaceuticals' quarterly Gross Margin came in at 98.14% in Q1 2026, down 186.0% year-on-year from 114.11% in Q1 2025, and down 1.86% quarter-over-quarter from 100.0% in Q1 2025.

Crinetics Pharmaceuticals has reported Gross Margin for 2 years, with the latest figure at 98.14% in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 79.04%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 86.85%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 91.79%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 82.22%
10 Crinetics Pharmaceuticals 3.59 Bn 3.59 Bn 10.53 Mn 98.14%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 98.14%
Mar 31, 2025 100.00%